N the past decade, exciting advances have been made in understanding the molecular events that can occur in the conversion of a normal cell to a tumor cell. Two classes of genes have been described: oncogenes and tumor suppressor genes, and it is established that the activities of both classes of genes affect intracellular signaling mechanisms. A series of oncogenes has been identified that represents mutations in normal cell receptors, G-proteins, tyrosine kinases, serine/threonine kinases, and transcription factors. Each of these proteins is involved in a normal signaling pathway, and mutations that convert the normal proteins (or proto-oncogenes) to oncogenes alter the signals being sent by that pathway. In glioblastomas, mutations and amplification of the epidermal growth factor EGF receptor have been described. 9 We and other researchers 11, 18, 34 have observed an increased expression of a number of growth factors in glioblastomas, but again there is no well-defined pattern. This suggests that proteins that control multiple systems (pleiotropic responses) might be involved. Protein kinase C (PKC) is just such a protein family and some of its isoforms (or isozymes) are activated by the tumor promoter phorbol ester (PMA).
Recent studies 24 have identified 10 isoforms of PKC that differ in structure and in activators. One group of isoforms includes PKC-␣, -␤I, -␤II, and -␥. [22] [23] [24] These isoforms have similar structures in which the amino-terminal half of the protein is a regulatory region whereas the carboxyl-terminal half is the catalytic portion. Enzymatic activity is dependent upon phosphatidylserine, calcium, and diacylglycerol or PMA. In studies conducted in this laboratory on the distribution of these four isoforms in glioblastoma cell lines, 20 the presence of PKC-␣ and PKC-␥ was established as was the absence of PKC-␤I and PKC-␤II. This paper focuses on the distribution of isoforms in the second group, comprising PKC-␦, PKC-⑀, PKC-⑀Ј, and PKC-. This group of isoforms is structurally different from the first group [22] [23] [24] 28 in that a sequence in the regulatory region is absent; this correlates with the absence of a requirement of calcium for enzyme activity. Protein kinase C-␦, with a molecular weight of 76 kD, does not require Ca ++25,26,28 but does have a requirement for phosphatidylserine and either diacylglycerol or PMA. 25 Protein kinase C-⑀, an isoform with a molecular weight of 90 kD, 17 ߜ Levels of protein kinase C (PKC) isoforms in eight human glioblastoma cell lines and two normal human glial cell cultures were determined. Earlier studies identified PKC-␣ and PKC-␥ in these cell lines but PKC-␤ was not present. In this study, PKC-⑀ and PKC-are demonstrated immunologically in these cell lines and also in two normal human glial cell cultures. Protein kinase C-␦ was not present. When levels of the four isoforms in the tumor cells were compared to levels in the normal cells, no increase was observed in PKC-␣ or PKC-␥, but PKC-⑀ was elevated three to 30 times in six of the eight tumors, and PKC-was elevated approximately two times in all of the tumors. Incubation of cell line A172 with phorbol ester for 6 hours resulted in a 48-fold maximum increase in the nuclear PKC-⑀ and a sevenfold increase in the plasma membrane fraction with no change in the cytoplasmic fraction. A similar incubation for 4 hours produced a 0.5-to onefold increase of PKC-in cytoplasmic, nuclear, and plasma membrane fractions. Other researchers have shown that overexpression of PKC-⑀ in fibroblasts results in tumorigenesis, and that blocking PKC-function inhibits deoxyribonucleic acid synthesis. These data suggest that alteration in the expression of PKC-⑀ and PKC-could be a factor in the conversion of normal glial cells to glioblastomas.
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I structure similar to PKC-␦, 28 is insensitive to Ca ++ , and is activated by diacylglycerol in the presence of either phosphatidylserine or arachidonic acid. 17 Protein kinase C-⑀Ј has a short sequence deleted at the amino terminal end. 28 Protein kinase C-is a Ca ++ -independent isoform with molecular weights of 67 kD 24, 27 and 80 kD, 33 which differs from the usual PKC structure in having only one cysteine-rich zinc finger region rather than the usual two. 27 This PKC isoform does not bind PMA 27, 33 or diacylglycerol 33 and does not translocate or down-regulate in response to PMA. 33 It may be part of a signal transduction pathway that involves phosphatidylinositol 3-kinase. 21 Properties of the PKC isoforms have been summarized elsewhere. 22, 24 In this study, using protein gel blot analysis, we have identified PKC-␣, -␥, -⑀, and -in two normal human glial cell cultures and in eight glioblastomas. When compared to the normal cells, the levels of PKC-⑀ were very elevated in 6 of the 8 tumors, whereas the levels of PKC-were moderately elevated in all of the tumors. Levels of both PKC-⑀ and PKC-were increased rather than down-regulated by PMA in the A172 glioblastoma cell line.
Materials and Methods

Cell Culture
The cell lines A172, A2781, A1207, A1235, U87MG, U138MG, and U373MG were obtained from outside sources;* the Tm3 cell line was cultured from a glioblastoma in this laboratory. Normal human glial (NHG)-1 and NHG-2 cells were cultured from tissue excised with seizure foci; they were used after approximately four to six passages and were positive for glial fibrillary acidic protein. Tumor cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and glucose (3.4 mg/L). A 20% FBS solution was used with the normal glial cultures. Nonessential amino acids were added to U87MG and U138MG cultures. For PMA treatments, cells were incubated in FBS-containing medium with 100 nM phorbol myristate acetate kept at 37˚C for the specified length of time.
Extracts of Cell Lines, Subcellular Fractionation, and Immunoblotting
Approximately 6 to 9 ϫ 10 7 cells in the preconfluent state from three 10-cm plates were used for total protein extraction. Cells were trypsinized, counted, centrifuged, and resuspended in phosphate buffered saline (PBS) at 4˚C. After two washings in PBS, cells were resuspended in 1 ml of Laemmli buffer, heated at 100˚ for 10 minutes, and stored at Ϫ20˚C. Protein concentrations measured with BCA protein assay reagent averaged 9 g/l, and 75 l was loaded in each 9-mm wide well. A common stock of extract for each cell preparation was used for the protein gel blot analysis of PKC-␣, -␥, -␦, -⑀, and -. Proteins were separated by electrophoresis on 8% acrylamide 0.1% sodium dodecyl sulfate gels and transferred to nitrocellulose membranes using an electrophoretic blotter. † Sheets were incubated with a blocking buffer, as described elsewhere, 20 stored overnight at 4˚C, washed, and then incubated with rabbit antibody to PKC-␣ and -␥ as described by Misra-Press, et al., 20 and with rabbit antibody to PKC-␦, -⑀, and -at 2 g/ml for 1 hour at 22˚C with shaking. After washing three times with PBS, horseradish peroxidase linked to goat anti-rabbit immunoglobulin ‡ was added for a 1-hour incubation period at 22˚C. After washing three times, reactive proteins were visualized with luminal from an ECL stain kit. § A SciScan densitometer was used to scan films; details of the procedure have been previously reported. 20 Affinity-purified rabbit antibodies to PKC-␣ and -␥ were used* and evidence for their specificity and their lack of cross-reactivity has been presented elsewhere. 12, 13 Rabbit antipeptide antibodies to rat PKC-⑀ and to PKC-as well as the respective blocking peptides were used, and the PKC-specific peptides of the carboxyl-terminal 12 residues (⑀) and carboxyl-terminal 16 residues () were added at 1 g/ml to the specific antibody. These residues were incubated at 4˚C for 1 hour before being added to the nitrocellulose sheet. More details on this procedure and the subcellular fractionation have been published. 20 The rabbit antipeptide antibody to human PKC-␦ as well as the baculovirus-produced human PKC-␦ protein and the corresponding peptide were used in the study; † similar conditions were employed for analysis.
Results
A series of eight human glioblastoma cell lines were used in this study of PKC isoforms. Rabbit antibodies and a chemiluminescent technique were used to visualize proteins of PKC isoforms. The object of these studies was to identify the isoforms that are expressed in these tumors, to compare levels of expression in tumors to levels in normal human glial cells, and to examine intracellular responses of some of the isoforms to cellular exposure to PMA.
Expression of PKC-␣, -␥, -⑀, and -in Human Glioblastomas and Human Normal Glial Cells
Levels of expression of PKC-␣ and PKC-␥ in the normal glial cells and in eight tumors are shown in Fig. 1 . Previous work has demonstrated that PKC-␣ and -␥, but not PKC-␤I or -␤II are expressed in glioblastomas. 20 These new data on total cell extracts are shown here to serve as a comparison with data on the PKC isoforms, ⑀ and . To determine whether there is overexpression of PKC-␣ in tumor cell versus normal human glial cells, densitometer readings were corrected for any variation in protein applied to the gel; afterward, tumor values were compared to the NHG cell value arbitrarily set at 1.0 (NGH-1) ( SciScan 5000 laser densitometer manufactured by U.S. Biochemical Corp., Cleveland, Ohio.
* Affinity-purified rabbit antibodies to PKC-␣ and -␥ were kindly provided by Dr. Alan Fields.
† Rabbit antipeptide antibody to human PKC-␦ and to human PKC-␦ and the baculovirus-produced human PKC-␦ protein were obtained from Oxford Biomedical Research Co., Rochester Hills, Michigan; corresponding peptide kindly provided by Dr. David Burns, Sphinx Pharmaceuticals Inc., Durham, North Carolina. 1). The value for a second human NHG-2 cell culture, analyzed in other experiments with A172 as an internal control, is also shown (Table 1 ). There is apparently no elevation of PKC-␣ protein levels in tumor cells compared to two normal cell cultures (Fig. 1A , Table 1 ). In a previous paper, the level of PKC-␣ messenger ribonucleic acid in glioblastomas was also the same as that in a different NHG cell, 20 and a similar conclusion was reached for PKC-␥ levels (Fig. 1B,  Table 1 ) when the doublet of approximately 78 to 80 kb had been shown to be the isoform. No investigation has determined whether this doublet is due to a phosphorylated form, as is seen with PKC-␦ and -⑀. 5 In this analysis, PKC-␥ was observed in all tumor extracts, but previously it was not observed in two of the same tumor extracts, 20 possibly due to its proteolytic sensitivity. 15, 16 As noted in Table 1 , no PKC-␤I or -␤II isoform is present in glioblastomas. 20 Isoform levels of PKC-⑀ in total cell extracts are shown in Fig. 2A and in Table 1 , in which it is apparent that in six of eight tumors the isoform level is elevated considerably above that present in NHG cells. The range of elevation is from three-to 30-fold greater than in normal cells. Multiple bands are visualized with this antibody, but the major band, which is present at around 90 kD in extracts of tumors A172 and A2781, is eliminated when the blocking peptide is added to the reaction mix ( Fig. 2A) . The commercial antibody was made with a carboxyl-terminal peptide and so would react with both PKC-⑀ and PKC-⑀Ј. 28 The PKC isoform is present in glioblastoma cells Fig. 1A . The use of PKC-⑀-specific rabbit antibody in the protein gel blot analysis is described in Methods. Lanes 1 to 3, underlined and labeled "blocked," are similar to adjacent lanes 1 to 3 except that ⑀-specific peptide (1 g/ml) was added. B: Levels of expression of PKC-are indicated in lanes 1 to 9; lanes 1 to 3, labeled "blocked," are similar to PKC-⑀ in A above, except that PKC--specific rabbit antibody was used in addition to -specific peptide (1 g/ml) for blocking.
as shown in Fig. 2B and Table 1 . The major band at approximately 80 kD in tumor cell lines A172 and A2781 is eliminated by the addition of the antigenic peptide. Of interest is the one-to twofold elevation of PKC-in all of the tumors compared to the NHG cells.
We were unable to observe the presence of PKC-␦ in extracts of the NHG cells or the tumors on immunoblotting. As shown in Fig. 3 , bands were present in the 76-kD region; however, in extracts of tumors A172 (lane 2) and A2781 (lane 3), these bands were not eliminated by preincubation of the antibody with the blocking peptide. The cell extracts used for immunoblotting with the PKC-␦ antibody were the same as those used for analysis of the other PKC isoforms. Figure 4 shows that preincubation with the peptide totally eliminated staining of the band of 10 g of baculovirus-produced human PKC-␦ (lane 4), as well as a band of the same size in a rat brain extract (lanes 1 and 2). All bands from tumor A2781 extract (Fig. 4, lane 3) show some decrease with blocking peptide, but as shown in Fig. 3, lane 3 , there was no effect of the peptide on the A2781 extract. If there was degradation of PKC-␦, one might predict that one or more of the lower molecular weight bands would disappear when the peptide was added; however, this did not occur (Fig. 3 ).
An accurate comparison of the relative levels of PKC-␣, -␥, -⑀, and -in a single cell line is not possible because we have no purified human isoforms and the affinities of the antibody preparations are not known. However, if we assume similar affinities and concentrations of the antibodies for the four PKC isoforms and we factor in times of exposure, the relative levels in the NGH-1 cells in which the PKC-⑀ level is arbitrarily set to one are 11 for PKC-␥, 18 for -, and 73 for -␣. Relative levels in NGH-2 and the eight glioblastomas would then be proportional to the values shown in Table 1 relative to these values. This suggests, but does not prove, that the predominant isoform in the NHG cells is ␣ and the next may be .
These values are only approximate and they represent protein levels, not activity levels.
Effect of PMA on Levels and Cellular Distribution of PKC-⑀ and -
The A172 glioblastoma cells were incubated with phorbol myristate acetate (100 nM), and aliquots were taken at varying times to examine cell fractionation and to determine levels of PKC-⑀ and PKC-. The results from using the antibody for PKC-⑀ show that low levels are present in cytosol, nucleus, and plasma membrane in control cells (Fig. 5 left and Table 2 ). Remarkable is the 48-fold increase of the isoform in nuclei and the sevenfold increase in the plasma membrane fraction after 6 hours. By 25 hours, the elevated levels have all but disappeared. Protein kinase Cshows a similar, but less dramatic increase in all of the cell fractions, reaching a twofold maximum in 4 hours (Fig. 5 right and Table 2 ).
Discussion
The tissue distribution of the various isoforms of PKC is apparently very specific. 23, 35 In the cerebellum of a rat brain, for example, all eight of 10 isoforms are present, but they can be localized in different regions, in different cells, and in different subcellular structures. 35 The first question in our studies involved identifying which isoforms of PKC were present in glioblastoma cell lines. We have presented data demonstrating the presence of PKC-␣, -␥, -⑀, and -in two NHG cell cultures as well as in eight glioblastoma cell cultures. Protein kinase C-␤ 20 and -␦ were absent. The second question posed was whether the level of any of the isoforms was altered in glioblastoma cell lines compared to NHG cells. We have found that the FIG. 3 . Protein gel blot analysis using a protein kinase C (PKC)-␦ antibody of extracts of normal human glial (NHG) cells and eight glioblastomas. In A and B, conditions were similar to those described in Fig. 2 except for the use of PKC-␦-specific rabbit antibody plus ␦-specific peptide (1 g/ml) for blocking. FIG. 4 . Protein gel blot analysis from which the reaction of an antibody to protein kinase C (PKC)-␦ with extracts of rat brain and glioblastoma and baculovirus-produced human PKC-␦ is demonstrated. In lanes 1 and 2, rat brain extract was diluted 1:4 and 1:1, respectively. Lane 3 shows the reaction of A2781 to glioblastoma cell extract; and in lane 4, baculovirusproduced human PKC-␦ (10 g) was used. Delta-specific peptide is seen to block lanes 1 to 4 (BLOCKED).
level of PKC-⑀ on the basis of total cellular protein per microgram was elevated in six of the eight tumors from three to 30 times the level in the NHG cells. We have also observed a twofold increase in the level of PKC-in all of the tumors. The levels of PKC-␣ and -␥ were similar in the tumors and the NHG cells. The relationship of the increase in concentration of a PKC isoform in glioblastomas to tumorigenesis is an attractive hypothesis based on the following fact and observations: namely, that several tumor promoters function through interaction with PKC, that PKC enzyme activity is probably higher in glioblastomas than in normal human glial cells, 6 that PKC stimulation can have pleiotropic effects, 22, 23 and that expression of many growth factors and transcription factors is elevated in glioblastomas. 11, 34 Further experiments will be necessary to determine whether there are elevated levels of PKC-⑀ and PKC-in glioblastomas that have not been in culture for long periods (as have these cell lines). Antisense oligonucleotides or expression plasmids should be tested for their ability to induce differentiation in glioblastoma cells.
A review of evidence indicating that some of the PKC isoforms are involved in cell proliferation supports the importance of our findings. When PKC-⑀ isoform was overexpressed in rat R6 embryo fibroblasts, cell morphology was altered, saturation density was increased, and growth in soft agar as well as tumorigenesis in nude mice was observed. 5, 19 Also of interest is the isolation of a 40-kD truncated form of PKC-⑀ from a small-cell carcinoma of the lung. 1 Thus, the elevated levels of PKC-⑀ that we have observed in glioblastoma cells might be a factor in tumorigenesis. Protein kinase C-, when overexpressed in NIH 3T3 cells, did not alter morphology, but did increase growth of cells in 0.5% serum as well as in soft agar. . Cellular fractionation occurred as described elsewhere. 20 The amounts of protein that were added were proportional to the amounts isolated in the fractions. C = cytosol; N = nucleus; P = plasma membrane. Right: Increased PKCprotein in A172 glioblastoma cellular fractions due to PMA. Conditions are similar to those described in Fig. 5 left. negative mutant of PKC-. 3 This mutant could also block the activation of the transcription factor NF-kB. 8 Overexpression of PKC-␥ (which was not increased in our tumors) in NIH 3T3 fibroblasts reduced the serum requirement for growth, increased saturation density, and enhanced tumorigenicity in nude mice. 29 In contrast to these PKC isoforms that increase cell mitogenesis, PKC-␣, when overexpressed in rat R6 cells and mouse BALB/C 3T3 fibroblasts, resulted in a slower growth rate and failed to allow cell growth in soft agar or in nude mice. 4, 10 In our tumor cell lines, PKC-␣ was not increased. In human erythroleukemia cells, PKC-␣ is apparently involved in cell differentiation as opposed to PKC-␤, which is involved in cell division. 13 Overexpression of PKC-␤ results in abnormal growth. 14 The suggestion that PKC-␣ may be related to cell differentiation rather than to cell proliferation could explain the finding that levels of PKC-␣ in gliomas decrease with increasing degrees of malignancy, and when present in a few glioblastoma cells, these cells were larger and more differentiated. 2 Thus the elevation of levels of PKC-⑀ in six of eight of the glioblastoma cell lines and the elevation of PKC-in all of our glioblastoma cell lines supports the hypothesis that these altered levels could be a factor in glioblastoma tumorigenesis.
The marked effect of PMA on the levels of PKC-⑀ in the A172 glioblastoma cell line was unexpected. By 6 hours, there was a 26-fold increase in the total level and a 46-fold increase in the nuclear fraction. The increase in PKC-⑀ after PMA stimulation has been seen by others. 1, 5 The small, 0.8-fold increase, rather than the down-regulation of total PKC-after 4 hours of exposure to PMA, was not unexpected because PKC-does not bind PMA or diacylglycerol and so must be involved in another signaling system. 21 With regard to the responses of the isoforms of PKC to PMA, one may suggest the following: the general phenomenon of tumor promotion by PMA may occur because PMA can down-regulate the level of PKC-␣ which may be involved in aspects of differentiation. At the same time, the PMA can increase the level of PKC isoforms that affect cell proliferation such as PKC-⑀ and -. If the level of PKC-␣ is much higher than the other isoforms, an increase in the latter due to PMA might not be suspected if the total activity of PKC is measured.
Our results differ from those of several other groups. Shimosawa, et al., 31 found PKC-␣ protein in four cell lines including A172 but PKC-␥ was absent in all cell lines. In this regard, PKC-␥ is more prone to proteolytic degradation than PKC-␣ or -␤. 15 ,16 In our first study, we did not detect PKC-␥ in two of eight tumors, but in the present study we have identified this isotype in all eight. Todo, et al., 32 examined PKC protein isoforms in frozen sections of six glioblastomas in which they found PKC-␣ in six tumors, PKC-␤ in six tumors, and PKC-␥ in four other tumors. We were unable to demonstrate PKC-␤ messenger ribonucleic acid or protein in our cell lines, and Benzil, et al., 2 were also unable to identify PKC-␤ in glioblastomas. We are well aware of the heterogeneity of cells in glioblastomas and that cell lines are selected for growth in vitro; therefore, they may not accurately represent the original tumor. However, an advantage that cell lines have for study is that the leads related to the conversion of NHG cells to glioblastomas can then be followed in cells that are more closely related to the tumors. Elevated PKC enzymatic activity has been demonstrated in glioblastomas compared to NHG cells. 6, 7 Finally, any therapeutic control of PKC activity must take into account the presence and function of the isoforms not only in the target tumor tissue but in normal tissues as well. Because some PKC isoforms are probably involved in signaling in many tissues, any therapeutic window would most likely be very narrow. Only a few inhibitors are currently known and specificity for a specific isoform is not established. More knowledge of the protein structure of the isoforms may lead to the design of more specific isoform inhibitors. In addition, more knowledge of the growth factors that activate pathways in glioblastomas specific for PKC-⑀ and -and knowledge of transcriptional responses that result from activation of these isoforms may help to elucidate the role they play in these glioblastomas.
